EXOZ EXOZYMES INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2010788 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-21.6%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-268.1%
ROA-149.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-41.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | $70,069 |
| R&D expense | $3.71M | $1.87M | $527,480 |
| SG&A expense | $6.01M | $4.06M | $1.34M |
| Operating income | -$9.72M | -$5.93M | -$1.80M |
| Pretax income | -$9.26M | -$5.86M | -$2.00M |
| Income tax | -$105,205 | — | $42,267 |
| Net income | -$9.16M | -$5.86M | -$2.04M |
| EBITDA | -$9.43M | -$5.66M | -$1.60M |
| EPS (basic) | -1.09 | -0.89 | -0.33 |
| EPS (diluted) | -1.09 | -0.89 | -0.33 |
| Weighted avg. shares (diluted) | 8.38M | 6.56M | 6.25M |
| Balance sheet | |||
| Cash & equivalents | $3.04M | $9.72M | $66,533 |
| Current assets | $3.94M | $10.82M | $1.21M |
| PP&E, net | $764,401 | $882,445 | $753,376 |
| Total assets | $5.97M | $13.03M | $3.56M |
| Current liabilities | $1.57M | $1.33M | $2.42M |
| Total liabilities | $2.57M | $2.61M | $3.94M |
| Shareholders' equity | $3.40M | $10.42M | -$384,319 |
| Shares outstanding | 8.41M | 8.37M | 6.25M |
| Cash flow statement | |||
| Operating cash flow | -$6.50M | -$8.51M | -$1.18M |
| Capital expenditure | $169,917 | $396,451 | $288,712 |
| Free cash flow | -$6.67M | -$8.90M | -$1.47M |
| Investing cash flow | -$150,218 | -$359,216 | -$311,167 |
| Financing cash flow | -$27,709 | $18.52M | $1.00M |
| Depreciation & amortization | $287,961 | $267,382 | $196,937 |
| Stock-based compensation | $1.99M | $1.13M | $281,538 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.